Optimizing Fertility on Testosterone Therapy: Maintaining Testicular Function, Size and Sperm Production

Why Fertility Planning Matters During Testosterone Therapy

Testosterone therapy can be life-changing for men with symptomatic testosterone deficiency. It can improve energy, mood, libido, sexual function, body composition, training response, and overall quality of life when used appropriately. However, testosterone therapy also changes the normal hormonal signaling between the brain and the testes.

For men who want to have children in the future, are currently trying to conceive, or simply want to maintain testicular function while on treatment, this needs to be discussed before or during therapy. The goal is not to create fear around testosterone. The goal is to make sure treatment is aligned with the patient's long-term goals.

Many men can use testosterone therapy while also taking steps to support testicular function. Others may be better served by fertility-preserving alternatives to testosterone, especially if actively trying to conceive. The right approach depends on timing, baseline hormone levels, semen analysis, age, symptoms, testicular function, and fertility goals.

How Testosterone Therapy Affects Intratesticular Physiology

The testes normally receive signals from the brain. The hypothalamus releases GnRH, which tells the pituitary gland to produce luteinizing hormone and follicle-stimulating hormone. Luteinizing hormone, or LH, stimulates Leydig cells in the testes to produce testosterone. Follicle-stimulating hormone, or FSH, works with high intratesticular testosterone to support sperm production.

When testosterone is taken from an outside source, the brain senses that testosterone levels are adequate and reduces its own signaling. LH and FSH usually decrease. This is expected physiology. As those signals decrease, the testes produce less testosterone internally and sperm production can slow significantly.

This does not mean the testes are permanently damaged. In many men, sperm production can recover after stopping testosterone, but recovery can take months and is not always predictable. This is why fertility planning is important before starting therapy and especially before trying to conceive.

Testicular Size Changes on TRT

Some men notice that the testes feel smaller or less full while on testosterone therapy. Not every man experiences this. The reduction in size happens because LH and FSH signaling are reduced, and the testes are less active internally. Because they are less active, they become smaller. In most cases, if this happens, size can be restored with various therapies or carefully discontinuing testosterone.

The clinical goal is to maintain testicular activity when that matters to the patient. This may mean preserving testicular size and comfort, maintaining intratesticular testosterone, supporting sperm production, or keeping future fertility options open.

Human Chorionic Gonadotropin (hCG)

Human chorionic gonadotropin (hCG or Pregnyl) is one of the most important tools for maintaining testicular function during testosterone therapy. It binds to the LH receptor in the testes and stimulates internal testosterone production. This internal testicular testosterone environment, called intratesticular testosterone, is important for testicular volume and sperm production.

Clinical studies show that relatively low doses of hCG can maintain intratesticular testosterone even when gonadotropins are suppressed. In one study, 250 IU every other day maintained intratesticular testosterone close to baseline, while 500 IU every other day increased intratesticular testosterone above baseline. This is why low-dose hCG is often used alongside testosterone in men who want to maintain testicular function.

hCG may also help preserve sperm production in selected men on testosterone therapy. In a clinical series of men using testosterone with low-dose hCG, semen parameters were maintained and no patients became azoospermic during follow-up. This does not guarantee fertility for every patient, but it supports hCG as a useful fertility-preserving strategy for men who need testosterone therapy.

Dosing And Monitoring hCG

hCG dosing should be individualized. A common approach for men on testosterone therapy is low-dose hCG several times per week. Many protocols use 250 to 500 IU every other day, sometimes twice a week, sometimes once a week. Some fertility-focused protocols use higher doses depending on sperm counts, testosterone levels, testicular response, and timing of fertility goals. The dosing protocol should be decided in consultation with your healthcare provider.

Smaller, more frequent hCG dosing is often preferred because it may provide steadier stimulation and reduce large hormonal swings, particularly estrogen. Higher or less frequent bolus dosing can produce more testosterone and estradiol fluctuation in some patients. The goal is not to use the highest dose. The goal is to use the lowest effective dose that supports the patient's goals.

Monitoring usually includes total testosterone, free testosterone when appropriate, estradiol, CBC, and symptom response. If fertility is an active concern, semen analysis is essential. Lab monitoring helps determine whether the hCG dose is helping, whether estradiol is rising too much, and whether the overall testosterone program is still balanced. Other biomarkers of fertility can also be used, such as inhibin-B, but an actual semen analysis is the gold standard.

Semen Analysis: The Most Important Fertility Test

Hormone levels are useful, but semen analysis is the direct way to assess sperm production. A man can feel well on testosterone and still have very low sperm counts. Another man may have acceptable testosterone levels but poor sperm production for reasons unrelated to testosterone therapy.

For men who want fertility in the near future, a baseline semen analysis before starting testosterone can be very helpful. It provides a starting point and can identify pre-existing fertility issues. If a man is already on testosterone and wants to conceive, semen analysis helps determine whether sperm production is adequate or whether treatment needs to change.

If pregnancy is a current goal, semen analysis is usually repeated every few months while treatment is being adjusted. Sperm production takes time, so changes in therapy may not be fully reflected immediately.

Clomiphene Citrate

Clomiphene citrate (Clomid) is a selective estrogen receptor modulator (SERM). Instead of replacing testosterone directly, it blocks estrogen feedback at the hypothalamus and pituitary. This encourages the brain to increase LH and FSH production, which then stimulates the testes to produce intratesticular testosterone and support sperm production.

Typical dosing varies, but common regimens include 25 mg every other day, 50 mg every other day, or other individualized schedules. Monitoring includes testosterone, LH, FSH, estradiol, CBC, symptoms, and semen analysis when fertility is a goal.

Enclomiphene

Enclomiphene is one of the two isomers that make up clomiphene citrate. It is the more anti-estrogenic component and has been studied as a fertility-preserving treatment for men with secondary hypogonadism. In clinical trials, enclomiphene increased intratesticular testosterone while maintaining LH, FSH, and sperm concentrations. This makes enclomiphene conceptually appealing for men who want to preserve fertility on testosterone therapy.

The main advantage of enclomiphene is that it may stimulate the body's own testosterone production while maintaining reproductive signaling. The main limitation is that long-term safety data and broad real-world outcomes are more limited than for standard testosterone therapy or clomiphene.

FSH and Combination Fertility Treatment

FSH directly supports the Sertoli cells in the testes, which are essential for sperm development. hCG acts more like LH and supports internal testosterone production. For some men, hCG alone is not enough to restore or maintain sperm production, especially when fertility is an active goal.

In fertility-focused care, FSH (such as Gonal-f) may be added to hCG when sperm production remains low after several months. This is most commonly used in men with hypogonadotropic hypogonadism or men recovering sperm production after testosterone or anabolic steroid suppression.

FSH therapy is more expensive. It is not routinely needed for every man on testosterone therapy, but it can be important for men actively trying to conceive when semen parameters remain poor despite hCG or SERM-based treatment.

Gonadorelin and Pulsatile GnRH

Gonadorelin is a synthetic form of GnRH. In normal physiology, GnRH is released by the brain in pulses. Those pulses tell the pituitary to release LH and FSH. When given in a truly pulsatile fashion, gonadorelin can restore LH and FSH production in selected men with hypothalamic causes of hypogonadism.

The challenge is that effective pulsatile GnRH therapy typically requires specialized pump-based delivery and careful management. It is not widely available and is not the most common strategy for men on testosterone therapy. It also requires a healthy pituitary gland.

Gonadorelin is best understood as a specialized fertility or endocrine therapy rather than a simple add-on to testosterone. For most men who want fertility preservation while on testosterone, hCG-based strategies are more commonly used. If the desire is just to maintain testicular size, gonadorelin may be a useful option.

Estradiol Balance

Estradiol (estrogen) is important for men. It supports bone health, brain function, libido, erectile function, cardiovascular physiology, and overall hormone balance. The goal is not to eliminate estrogen. The goal is to keep estradiol in a healthy range and avoid symptoms from levels that are too high or too low.

Estradiol can rise during testosterone therapy or hCG therapy because some testosterone is converted to estradiol by the aromatase enzyme. This conversion is influenced by testosterone level, hCG dose, body fat, genetics, medications, alcohol intake, and other factors.

Symptoms of high estradiol can include breast tenderness, water retention, mood changes, and sometimes sexual function changes. Symptoms of low estradiol can include joint pain, low libido, erectile difficulty, mood changes, fatigue, and long-term bone health concerns.

Aromatase Inhibitors

Aromatase inhibitors such as anastrozole can lower estradiol by blocking the conversion of testosterone into estradiol. They can be useful in selected men with clearly elevated estradiol and symptoms. However, they should not be used casually or automatically.

Estradiol is essential for bone health in men. Over-suppressing estradiol can cause joint pain, low libido, mood changes, and potential long-term bone concerns. For this reason, the first step when estradiol is high during hCG therapy is often to adjust the hCG dose or dosing frequency rather than immediately adding an aromatase inhibitor.

When aromatase inhibitors are used, they should generally be low dose, symptom-guided, and monitored with labs. The target is balance, not suppression.

When Fertility is a Future Goal

If fertility is a future goal but not an immediate goal, some men may continue testosterone therapy while using hCG to maintain testicular activity. A baseline semen analysis can be considered, especially if the patient has never had children, has a history of fertility problems, or wants a clearer fertility plan.

The patient should understand that hCG may help maintain testicular function and sperm production, but it is not a guarantee. If fertility becomes an active goal, semen analysis becomes more important and treatment may need to be adjusted. There are effective at-home solutions for fertility testing.

When Fertility is a Current Goal

Men who are actively trying to conceive should be cautious with exogenous testosterone. Testosterone therapy can significantly suppress sperm production and may cause severe oligospermia or azoospermia. For this reason, many guidelines recommend avoiding testosterone therapy in men who are actively trying to conceive.

Common fertility-preserving options include clomiphene, enclomiphene when available, hCG, and hCG plus FSH when needed. Some men who are already on testosterone may need to stop testosterone and transition to a fertility-focused regimen. The exact plan depends on semen analysis, hormone levels, timeline, age of the couple, female partner factors, and whether assisted reproduction is being considered.

Recovery of sperm production after stopping testosterone can take months. In some men, especially those who are older or have used testosterone for longer periods, recovery may take longer. Early planning is therefore much better than waiting until pregnancy is urgently desired.

Monitoring Schedule

Monitoring should be individualized, but a practical approach may include baseline total testosterone, free testosterone when appropriate, LH, FSH, estradiol, CBC, CMP, PSA when appropriate, and semen analysis if fertility is a concern.

After starting or changing testosterone, hCG, clomiphene, enclomiphene, or aromatase inhibitor therapy, labs are commonly repeated in about 4 to 8 weeks. Once stable, monitoring is usually spaced out.

For men actively trying to conceive, semen analysis is often repeated every 2 to 3 months because sperm development takes time. For men using aromatase inhibitors, bone health and estradiol levels should be monitored carefully, especially if treatment is prolonged.

What Patients Should Not Do

Patients should not adjust testosterone, hCG, clomiphene, enclomiphene, FSH, or aromatase inhibitor doses on their own. These medications affect multiple hormonal pathways and can create problems if dosing is too high, too low, or poorly timed.

Patients should also avoid assuming that a normal testosterone level means fertility is normal. Testosterone and sperm production are related, but they are not the same thing. Semen analysis is the key test when fertility matters.

Men should also be cautious with gray-market or research-chemical hormone products. Fertility medications should come from reliable pharmacies and be managed with appropriate lab monitoring.

A Better Way to Think About Testosterone and Fertility

Testosterone therapy and fertility planning do not have to be in conflict, but they do need to be managed thoughtfully. Exogenous testosterone can suppress LH, FSH, intratesticular testosterone, and sperm production. However, medications such as hCG, clomiphene, enclomiphene, and FSH can help preserve or restore testicular signaling in selected patients.

At the Performance Medicine Institute, we help men choose testosterone and fertility strategies based on symptoms, hormone patterns, semen analysis, body composition, estradiol balance, and long-term goals. The goal is to improve quality of life while protecting future options.

If you are on testosterone therapy, considering testosterone therapy, or thinking about fertility in the future, we can help create a plan that fits your goals. Reach out for more information.

References

• Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602.
• Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647-650.
• Kohn TP, Louis MR, Pickett SM, Lindgren MC, Kohn JR, Pastuszak AW, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351-357.e1.
• Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685.
• Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
• Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. 2014;192(3):875-879.
• Wheeler KM, Smith RP, Kumar RA, Setia S, Costabile RA, Kavoussi PK. A comparison of secondary polycythemia in hypogonadal men treated with clomiphene citrate versus testosterone replacement: a multi-institutional study. J Urol. 2017;197(4):1127-1131.